Autologous Transplantation Versus Allogeneic Transplantation in Patients With Follicular Lymphoma Experiencing Early Treatment Failure

被引：53

作者：

Smith, Sonali M. ^{[1
]}

Godfrey, James ^{[2
]}

Ahn, Kwang Woo ^{[3
,4
]}

DiGilio, Alyssa ^{[3
]}

Ahmed, Sairah ^{[5
]}

Agrawal, Vaibhav ^{[6
]}

Bachanova, Veronika ^{[7
]}

Bacher, Ulrike ^{[8
,9
]}

Bashey, Asad ^{[10
]}

Bolanos-Meade, Javier ^{[11
]}

Cairo, Mitchell ^{[12
]}

Chen, Andy ^{[13
]}

Chhabra, Saurabh ^{[14
]}

Copelan, Edward ^{[15
]}

Dahi, Parastoo B. ^{[16
]}

Aljurf, Mahmoud ^{[17
]}

Farooq, Umar ^{[18
]}

Ganguly, Siddhartha ^{[19
]}

Hertzberg, Mark ^{[20
]}

Holmberg, Leona ^{[21
]}

Inwards, David ^{[22
]}

Kanate, Abraham S. ^{[23
]}

Karmali, Reem ^{[24
]}

Kenkre, Vaishalee P. ^{[25
]}

Kharfan-Dabaja, Mohamed A. ^{[26
]}

Klein, Andreas ^{[27
]}

Lazarus, Hillard M. ^{[28
]}

Mei, Matthew ^{[29
]}

Mussetti, Alberto ^{[30
]}

Nishihori, Taiga ^{[26
]}

Geethakumari, Praveen Ramakrishnan ^{[31
]}

Saad, Ayman ^{[32
]}

Savani, Bipin N. ^{[33
]}

Schouten, Harry C. ^{[34
]}

Shah, Nirav ^{[14
]}

Urbano-Ispizua, Alvaro ^{[35
,36
,37
]}

Vij, Ravi ^{[38
]}

Vose, Julie ^{[39
]}

Sureda, Anna ^{[40
]}

Hamadani, Mehdi ^{[3
]}

机构：

[1] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA

[2] Univ Chicago Med, Chicago, IL USA

[3] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, 9200 West Wisconsin Ave,Suite C5500, Milwaukee, WI 53226 USA

[4] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA

[7] Univ Minnesota, Med Ctr, Bone & Marrow Transplant Program, Minneapolis, MN 55455 USA

[8] Univ Bern, Univ Hosp Bern, Inselspital, Dept Hematol, Bern, Switzerland

[9] Univ Canc Ctr Hamburg, Interdisciplinary Clin Stem Cell Transplantat, Hamburg, Germany

[10] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA

[11] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[12] New York Med Coll, Dept Pediat, Div Pediat Hematol Oncol & Stem Cell Transplantat, Valhalla, NY 10595 USA

[13] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[14] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[15] Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[16] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA

[17] King Faisal Specialist Hosp & Res Ctr, Dept Oncol, Riyadh, Saudi Arabia

[18] Univ Iowa Hosp & Clin, Div Hematol Oncol & Blood & Marrow Transplantat, Iowa City, IA 52242 USA

[19] Univ Kansas, Med Ctr, Blood & Marrow Transplantat, Div Hematol & Oncol, Kansas City, KS 66103 USA

[20] Prince Wales Hosp, Dept Haematol, Randwick, NSW, Australia

[21] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[22] Mayo Clin, Div Hematol, Rochester, MN USA

[23] West Virginia Univ, Osborn Hematopoiet Malignancy & Transplantat Prog, Morgantown, WV USA

[24] Northwestern Univ, Chicago, IL 60611 USA

[25] Univ Wisconsin, Div Hematol Oncol, Madison, WI USA

[26] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA

[27] Tufts Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA USA

[28] Case Western Reserve Univ, Univ Hosp Cleveland, Med Ctr, Seidman Canc Ctr, Cleveland, OH 44106 USA

[29] City Hope Natl Med Ctr, Duarte, CA USA

[30] Ist Ricovero & Cura Carattere Sci IRCCS Fdn Natl, Dept Hematol & Pediat Oncohematol, Milan, Italy

[31] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA

[32] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA

[33] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA

[34] Acad Ziekenhuis, Dept Hematol, Maastricht, Netherlands

[35] Univ Barcelona, Hosp Clin, Dept Hematol, Barcelona, Spain

[36] August Pi & Sunyer Inst Biomed Res, Barcelona, Spain

[37] Josep Carreras Inst Res, Barcelona, Spain

[38] Washington Univ, Sch Med, Div Hematol & Oncol, St Louis, MO USA

[39] Nebraska Med, Omaha, NE USA

[40] Catalan Inst Oncol Hosp, Dept Hematol, Barcelona, Spain

来源：

CANCER | 2018年 / 124卷 / 12期

关键词：

allogeneic transplantation; autologous transplantation; chemoimmunotherapy; early treatment failure; follicular lymphoma; rituximab; STEM-CELL TRANSPLANTATION; TERM-FOLLOW-UP; EARLY RELAPSE; HIGH-RISK; SURVIVAL; RITUXIMAB; GRADE; IDELALISIB; REMISSION; OUTCOMES;

D O I：

10.1002/cncr.31374

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: Early treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high-risk group of patients with an expected 5-year overall survival (OS) rate of approximately 50%. Transplantation is an established option for relapsed FL, but its efficacy in this specific ETF FL population has not been previously evaluated. METHODS: This study compared autologous hematopoietic stem cell transplantation (auto-HCT) with either matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (allo-HCT) as the first transplantation approach for patients with ETF FL (age >= 18 years) undergoing auto-HCT or allo-HCT between 2002 and 2014. The primary endpoint was OS. The secondary endpoints were progression-free survival, relapse, and nonrelapse mortality (NRM). RESULTS: Four hundred forty FL patients had ETF (auto-HCT, 240; MSD hematopoietic stem cell transplantation [HCT], 105; and MUD HCT, 95). With a median follow-up of 69 to 73 months, the adjusted probability of 5-year OS was significantly higher after auto-HCT (70%) or MSD HCT (73%) versus MUD HCT (49%; P=.0008). The 5-year adjusted probability of NRM was significantly lower for auto-HCT (5%) versus MSD (17%) or MUD HCT (33%; P<.0001). The 5-year adjusted probability of disease relapse was lower with MSD (31%) or MUD HCT (23%) versus auto-HCT (58%; P<.0001). CONCLUSIONS: Patients with high-risk FL, as defined by ETF, undergoing auto-HCT for FL have low NRM and a promising 5-year OS rate (70%). MSD HCT has lower relapse rates than auto-HCT but similar OS. (C) 2018 American Cancer Society.

引用

页码：2541 / 2551

页数：11

共 29 条

[1] Defining the Intensity of Conditioning Regimens: Working Definitions [J].

Bacigalupo, Andrea ;

Ballen, Karen ;

Rizzo, Doug ;

Giralt, Sergio ;

Lazarus, Hillard ;

Ho, Vincent ;

Apperley, Jane ;

Slavin, Shimon ;

Pasquini, Marcelo ;

Sandmaier, Brenda M. ;

Barrett, John ;

Blaise, Didier ;

Lowski, Robert ;

Horowitz, Mary .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (12) :1628-1633

[2] Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis [J].

Casulo, Carla ;

Friedberg, Jonathan W. ;

Ahn, Kwang W. ;

Flowers, Christopher ;

DiGilio, Alyssa ;

Smith, Sonali M. ;

Ahmed, Sairah ;

Inwards, David ;

Aljurf, Mahmoud ;

Chen, Andy, I ;

Choe, Hannah ;

Cohen, Jonathon ;

Copelan, Edward ;

Farooq, Umar ;

Fenske, Timothy S. ;

Freytes, Cesar ;

Gaballa, Sameh ;

Ganguly, Siddhartha ;

Jethava, Yogesh ;

Kamble, Rammurti T. ;

Kenkre, Vaishalee P. ;

Lazarus, Hillard ;

Lazaryan, Aleksandr ;

Olsson, Richard F. ;

Rezvani, Andrew R. ;

Rizzieri, David ;

Seo, Sachiko ;

Shah, Gunjan L. ;

Shah, Nina ;

Solh, Melham ;

Sureda, Anna ;

William, Basem ;

Cumpston, Aaron ;

Zelenetz, Andrew D. ;

Link, Brian K. ;

Hamadani, Mehdi .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (06) :1163-1171

[3] Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study [J].

Casulo, Carla ;

Byrtek, Michelle ;

Dawson, Keith L. ;

Zhou, Xiaolei ;

Farber, Charles M. ;

Flowers, Christopher R. ;

Hainsworth, John D. ;

Maurer, Matthew J. ;

Cerhan, James R. ;

Link, Brian K. ;

Zelenetz, Andrew D. ;

Friedberg, Jonathan W. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (23) :2516-U55

[4] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[5] Stem Cell Transplantation for Follicular Lymphoma Relapsed/Refractory After Prior Rituximab [J].

Evens, Andrew M. ;

Vanderplas, Ann ;

LaCasce, Ann S. ;

Crosby, Allison L. ;

Nademanee, Auayporn P. ;

Kaminski, Mark S. ;

Abel, Gregory A. ;

Millenson, Michael ;

Czuczman, Myron S. ;

Rodriguez, Maria A. ;

Niland, Joyce ;

Zelenetz, Andrew D. ;

Gordon, Leo I. ;

Friedberg, Jonathan W. .

CANCER, 2013, 119 (20) :3662-3671

[6] New treatment options have changed the survival of patients with follicular lymphoma [J].

Fisher, RI ;

LeBlanc, M ;

Press, OW ;

Maloney, DG ;

Unger, JM ;

Miller, TP .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8447-8452

[7] Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy [J].

Gopal, Ajay K. ;

Kahl, Brad S. ;

Flowers, Christopher R. ;

Martin, Peter ;

Ansell, Stephen M. ;

Abella-Dominicis, Esteban ;

Koh, Brian ;

Ye, Wei ;

Barr, Paul M. ;

Salles, Gilles A. ;

Friedberg, Jonathan W. .

BLOOD, 2017, 129 (22) :3037-3039

[8] Allogeneic transplants in follicular lymphoma: Higher risk of disease progression after reduced-intensity compared to myeloablative conditioning [J].

Hari, Parameswaran ;

Carreras, Jeanette ;

Zhang, Mei-Jie ;

Gale, Robert Peter ;

Bolwell, Brian J. ;

Bredeson, Christopher N. ;

Burns, Linda J. ;

Cairo, Mitchell S. ;

Freytes, Cesar O. ;

Goldstein, Steven C. ;

Hale, Gregory A. ;

Inwards, David J. ;

LeMaistre, Charles F. ;

Maharaj, Dipnarine ;

Marks, David I. ;

Schouten, Harry C. ;

Slavin, Shimon ;

Vose, Julie M. ;

Lazarus, Hillard M. ;

van Besien, Koen .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) :236-245

[9] Follicular lymphoma: evolving therapeutic strategies [J].

Kahl, Brad S. ;

Yang, David T. .

BLOOD, 2016, 127 (17) :2055-2063

[10] Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors [J].

Kanate, Abraham S. ;

Mussetti, Alberto ;

Kharfan-Dabaja, Mohamed A. ;

Ahn, Kwang W. ;

DiGilio, Alyssa ;

Beitinjaneh, Amer ;

Chhabra, Saurabh ;

Fenske, Timothy S. ;

Freytes, Cesar ;

Gale, Robert Peter ;

Ganguly, Siddhartha ;

Hertzberg, Mark ;

Klyuchnikov, Evgeny ;

Lazarus, Hillard M. ;

Olsson, Richard ;

Perales, Miguel-Angel ;

Rezvani, Andrew ;

Riches, Marcie ;

Saad, Ayman ;

Slavin, Shimon ;

Smith, Sonali M. ;

Sureda, Anna ;

Yared, Jean ;

Ciurea, Stefan ;

Armand, Philippe ;

Salit, Rachel ;

Bolanos-Meade, Javier ;

Hamadani, Mehdi .

BLOOD, 2016, 127 (07) :938-947

← 1 2 3 →